Last reviewed · How we verify
Adoport
At a glance
| Generic name | Adoport |
|---|---|
| Also known as | Tacrolimus |
| Sponsor | Barts & The London NHS Trust |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- OPTIMIZATION of the Dose of tacroliMUS by Bayesian Prediction in Renal Transplant Patients Including Pharmacogenetic Variables (Phase 4)
- Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation (Phase 4)
- Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day. (Phase 4)
- A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation (Phase 4)
- ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adoport CI brief — competitive landscape report
- Adoport updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI